Human GPC3(Glypican 3) ELISA Kit

Description: A sandwich quantitative ELISA assay kit for detection of Human Glypican 3 (GPC3) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: A sandwich quantitative ELISA assay kit for detection of Human Glypican 3 (GPC3) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Glypican 3 (GPC3) in samples from Serum, plasma, tissue homogenates and other biological fluids with no significant corss-reactivity with analogues from other species.

Description: A sandwich ELISA kit for quantitative measurement of Human GPC3 (Glypican 3) in samples from Serum, Plasma, Cell supernatant

Description: A sandwich ELISA kit for detection of Glypican 3 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Glypican-3 (GPC3) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Glypican-3 (GPC3) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Glypican-3 (GPC3) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Rattus;Sensitivity: 0.094 ng/ml

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Mus ;Sensitivity: 0.094 ng/ml

Description: Quantitativesandwich ELISA kit for measuring Rat Glypican-3 (GPC3) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Description: Quantitativesandwich ELISA kit for measuring Rat Glypican-3(GPC3) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Description: A sandwich quantitative ELISA assay kit for detection of Rat Glypican 3 (GPC3) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: A sandwich quantitative ELISA assay kit for detection of Rat Glypican 3 (GPC3) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Rat Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Rat Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Rat Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Rat Glypican 3 (GPC3) in serum, plasma, tissue homogenates and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Rat Glypican 3 (GPC3) in samples from serum, plasma, tissue homogenates and other biological fluids with no significant corss-reactivity with analogues from other species.

Description: A sandwich quantitative ELISA assay kit for detection of Mouse Glypican 3 (GPC3) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: A sandwich quantitative ELISA assay kit for detection of Mouse Glypican 3 (GPC3) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: A sandwich ELISA kit for quantitative measurement of Rat GPC3 (Glypican 3) in samples from Serum, Plasma, Cell supernatant

Description: A sandwich ELISA kit for detection of Glypican 3 from Rat in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: A sandwich ELISA kit for quantitative measurement of Mouse GPC3 (Glypican 3) in samples from Serum, Plasma, Cell supernatant

Description: A sandwich CLIA kit for quantitative measurement of Human GPC3 (Glypican 3) in samples from Serum, Plasma, Cell supernatant

Description: Recombinant Rat Glypican-3(Gpc3),partial expressed in Yeast

Description: GPC3 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 544 amino acids (25-559a.a.) and having a molecular mass of 61.8kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa). GPC3 is expressed with a 6 amino acids His tag at C-Terminus and purified by proprietary chromatographic techniques.

Description: GPC3 is a cell surface proteoglycan that bears heparan sulfate. This protein may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. Members of the glypican-related integral membrane proteoglycan family contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol (GPI) linkage. These proteins may play a role in the control of cell division, growth regulation, and tumor predisposition. Deletion mutations in GPC3 are the cause of Simpson-Golabi-Behmel syndrome (SGBS), also known as Simpson dysmorphia syndrome (SDYS). SGBS is a condition characterized by pre- and postnatal overgrowth (gigantism) with visceral and skeletal anomalies.

Description: Cell surface proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: GPC3 is a cell surface proteoglycan that bears heparan sulfate. This protein may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. Members of the glypican-related integral membrane proteoglycan family contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol (GPI) linkage. These proteins may play a role in the control of cell division, growth regulation, and tumor predisposition. Deletion mutations in GPC3 are the cause of Simpson-Golabi-Behmel syndrome (SGBS), also known as Simpson dysmorphia syndrome (SDYS). SGBS is a condition characterized by pre- and postnatal overgrowth (gigantism) with visceral and skeletal anomalies.

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 is a proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition. [UniProt]

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm's tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm�s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm's tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm�s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm's tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm�s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm's tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm�s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilms tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilm s tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilm s tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that of follicular adenoma. In contrast, GPC3 is not expressed in anaplastic carcinoma.

Description: Primary antibody against Glypican-3(GPC3/863), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), 1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Concentration: 0.2mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), Concentration: 0.2mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863), CF647 conjugate, Concentration: 0.1mg/mL

Description: Recombinant Human Glypican 3 expressed in: E.coli

Description: Recombinant Mouse Glypican 3 expressed in: E.coli

Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Description: Quantitativesandwich ELISA kit for measuring Human Glypican-3, GPC-3 in samples from serum, urine, cell culture supernates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Description: Quantitativesandwich ELISA kit for measuring Human Glypican-3, GPC-3 in samples from serum, urine, cell culture supernates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Description: A sandwich CLIA kit for quantitative measurement of Rat GPC3 (Glypican 3) in samples from Serum, Plasma, Cell supernatant

Description: A Mouse monoclonal antibody against Human Glypican 3 (GPC3)

Description: A Rabbit polyclonal antibody against Human Glypican 3 (GPC3)

Description: A sandwich CLIA kit for quantitative measurement of Mouse GPC3 (Glypican 3) in samples from Serum, Plasma, Cell supernatant

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.094 ng/ml

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.094 ng/ml

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 46.875pg/ml

Description: Recombinant Pan troglodytes Glypican-3 (GPC3) expressed in Mammalian cell

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), 1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Concentration: 0.2mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), Concentration: 0.2mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Glypican-3(GPC3/863 + 1G12), CF647 conjugate, Concentration: 0.1mg/mL